MedTrace Logo

Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis

NCT02560311 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2015-09-25

No results posted yet for this study

Summary

The aim of this study is to analyze cases of human epidermal growth factor receptor (HER) 2-positive metastatic breast cancer (MBC) of the last 10 years at the University Hospital of Zurich to assess the efficacy of the treatment with trastuzumab in HER2-positive MBC and to find out associations between different variables and the outcome. The aim is to find out probable prognostic factors and patterns of disease progression. Prognostic factors could optimize treatment approaches and result in a delay of disease progression.

Conditions

Interventions

OTHER

observation

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konstantin J Dedes, Dr.med. · UniversitätsSpital Zürich, Klinik für Gynäkologie

  • Bernhard Pestalozzi, Prof.Dr.med. · UniversitätsSpital Zürich, Klinik für Onkologie

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-09-30
Completion
2016-02-29

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02560311 on ClinicalTrials.gov